Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients.

IF 2.9 4区医学 Q2 DERMATOLOGY

Journal of Dermatological Treatment Pub Date : 2022-09-01 Epub Date: 2022-07-14 DOI:10.1080/09546634.2022.2071823

Jonette Keri, Fran E Cook-Bolden, Lawrence Green, Leon H Kircik, Hilary Baldwin, William Philip Werschler, Eric Guenin, Radhakrishnan Pillai, Varsha Bhatt

{"title":"Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients.","authors":"Jonette Keri, Fran E Cook-Bolden, Lawrence Green, Leon H Kircik, Hilary Baldwin, William Philip Werschler, Eric Guenin, Radhakrishnan Pillai, Varsha Bhatt","doi":"10.1080/09546634.2022.2071823","DOIUrl":null,"url":null,"abstract":"Background: Acne prevalence may be higher in overweight/obese individuals, potentially due to hormonal, inflammatory, and/or dietary factors. However, the effects of body mass index (BMI) on topical acne treatments are largely unknown.Methods: Post hoc analyses of changes in inflammatory/noninflammatory lesions and treatment success were conducted using phase 3 data: clindamycin phosphate/benzoyl peroxide (CP/BPO) 1.2%/3.75% gel (NCT01701024); tretinoin 0.05% lotion (NCT02965456 and NCT02932306; pooled); and tazarotene 0.045% lotion (NCT03168321 and NCT03168334; pooled). Data were analyzed by BMI subgroups: <25kg/m2 (underweight-to-normal), 25-<30kg/m2 (overweight), and ≥30kg/m2 (obese).Results: Among participants analyzed (CP/BPO = 495; tretinoin = 1,636; tazarotene = 1,612), ∼20-25% were overweight and 15-20% were obese. At week 12, mean percent changes from baseline in inflammatory lesions were: CP/BPO (overweight: -63.2%, obese: -56.0%); tretinoin (-57.6%, -53.1%); tazarotene (-59.9%, -56.8%). Mean changes in noninflammatory lesions were: CP/BPO (-54.2%, -50.8%); tretinoin (-51.6%, -44.9%); tazarotene (-56.7%, -54.6%). Treatment success rates with active treatment ranged from 16.2% to 33.5% across BMI groups.Conclusions: CP/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, and tazarotene 0.045% lotion were all effective in reducing acne lesions by ≥45% in overweight/obese patients with moderate-to-severe acne, comparable to the underweight-to-normal group. Efficacy of these topical acne treatments is not greatly impacted by BMI and may be affected more by the formulation.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2790-2799"},"PeriodicalIF":2.9000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2022.2071823","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acne prevalence may be higher in overweight/obese individuals, potentially due to hormonal, inflammatory, and/or dietary factors. However, the effects of body mass index (BMI) on topical acne treatments are largely unknown.

Methods: Post hoc analyses of changes in inflammatory/noninflammatory lesions and treatment success were conducted using phase 3 data: clindamycin phosphate/benzoyl peroxide (CP/BPO) 1.2%/3.75% gel (NCT01701024); tretinoin 0.05% lotion (NCT02965456 and NCT02932306; pooled); and tazarotene 0.045% lotion (NCT03168321 and NCT03168334; pooled). Data were analyzed by BMI subgroups: <25kg/m² (underweight-to-normal), 25-<30kg/m² (overweight), and ≥30kg/m² (obese).

Results: Among participants analyzed (CP/BPO = 495; tretinoin = 1,636; tazarotene = 1,612), ∼20-25% were overweight and 15-20% were obese. At week 12, mean percent changes from baseline in inflammatory lesions were: CP/BPO (overweight: -63.2%, obese: -56.0%); tretinoin (-57.6%, -53.1%); tazarotene (-59.9%, -56.8%). Mean changes in noninflammatory lesions were: CP/BPO (-54.2%, -50.8%); tretinoin (-51.6%, -44.9%); tazarotene (-56.7%, -54.6%). Treatment success rates with active treatment ranged from 16.2% to 33.5% across BMI groups.

Conclusions: CP/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, and tazarotene 0.045% lotion were all effective in reducing acne lesions by ≥45% in overweight/obese patients with moderate-to-severe acne, comparable to the underweight-to-normal group. Efficacy of these topical acne treatments is not greatly impacted by BMI and may be affected more by the formulation.

查看原文本刊更多论文

身体质量指数对三种局部痤疮治疗的疗效和耐受性:包括超重和肥胖患者的事后分析。

背景:痤疮在超重/肥胖人群中的患病率可能更高，可能是由于激素、炎症和/或饮食因素。然而，身体质量指数(BMI)对局部痤疮治疗的影响在很大程度上是未知的。方法:使用3期数据对炎症/非炎症病变的变化和治疗成功率进行事后分析:克林霉素磷酸/过氧化苯甲酰(CP/BPO) 1.2%/3.75%凝胶(NCT01701024);维甲酸0.05%洗剂(NCT02965456和NCT02932306;池);0.045%他沙罗汀洗剂(NCT03168321和NCT03168334;池)。数据按BMI亚组进行分析:2(体重过轻至正常)、25-2(超重)和≥30kg/m2(肥胖)。结果:在分析的参与者中(CP/BPO = 495;维甲酸= 1636;他zarotene = 1612)，超重~ 20-25%，肥胖15-20%。在第12周，炎性病变与基线相比的平均百分比变化如下:CP/BPO(超重:-63.2%，肥胖:-56.0%);维甲酸(-57.6%，-53.1%);他zarotene(-59.9%， -56.8%)。非炎性病变的平均变化为:CP/BPO (-54.2%， -50.8%);维甲酸(-51.6%，-44.9%);他沙罗汀(-56.7%，-54.6%)。在BMI组中，积极治疗的成功率从16.2%到33.5%不等。结论:CP/BPO 1.2%/3.75%凝胶、维甲酸0.05%洗剂、他zarotene 0.045%洗剂对超重/肥胖合并中重度痤疮患者的痤疮病变减少≥45%，与体重过轻至正常组相当。这些局部痤疮治疗的功效不受体重指数的影响很大，可能受配方的影响更大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Dermatological Treatment 医学-皮肤病学

CiteScore

6.50

自引率

0.00%

发文量

145

审稿时长

6-12 weeks

期刊介绍： The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.